HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Gillette

This article was originally published in The Rose Sheet

Executive Summary

Gillette: Used no laboratory animals in testing consumer products or ingredients during the 1996 reporting period (Oct. 1, 1995 through Sept. 30, 1996), according to the company's 1996 safety testing report. Gillette called the results a "significant achievement" since "new product development was at an all-time high" during the reporting period. Gillette introduced 46 new products or product lines "that did not rely on new laboratory testing," the report states. In 1996, the firm said it invested more than $1 mil. to fund research for the development and validation of alternative testing methods. During the year, Gillette patented a human regenerating eye cell line, similar to the corneal epithelium, to replace the Draize eye test. The company noted that it is also evaluating the development of a conjunctival eye cell line...

You may also be interested in...



OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Chart: Weekly Trademark Review -- Nov. 2, 2010

Weekly Trademark Review
UsernamePublicRestriction

Register

RS004045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel